Multi-zone stimulation implant system and method

Information

  • Patent Grant
  • 8380312
  • Patent Number
    8,380,312
  • Date Filed
    Thursday, December 30, 2010
    13 years ago
  • Date Issued
    Tuesday, February 19, 2013
    11 years ago
Abstract
Various embodiments of an implant system are provided. The implant, such as a mesh implant, can include a support structure, e.g., mesh sling or implant, one or more stimulation elements (e.g., leads), and an energizing element. Leads or electrodes can be positioned in desired stimulation zones of the implant. As such, the implant can include multiple electrically isolated mesh electrode pads or regions.
Description
FIELD OF THE INVENTION

The present invention relates generally to surgical methods and apparatus and, more specifically, to surgical implants or mesh having multiple stimulation zones defined therein.


BACKGROUND OF THE INVENTION

Pelvic health for men and women is a medical area of increasing importance, at least in part due to an aging population. Examples of common pelvic ailments include incontinence (e.g., fecal and urinary), pelvic tissue prolapse (e.g., female vaginal prolapse), and conditions of the pelvic floor.


Urinary incontinence can further be classified as including different types, such as stress urinary incontinence (SUI), urge urinary incontinence, mixed urinary incontinence, among others. Other pelvic floor disorders include cystocele, rectocele, enterocele, and prolapse such as anal, uterine and vaginal vault prolapse. A cystocele is a hernia of the bladder, usually into the vagina and introitus. Pelvic disorders such as these can result from weakness or damage to normal pelvic support systems.


Urinary incontinence can be characterized by the loss or diminution in the ability to maintain the urethral sphincter closed as the bladder fills with urine. Male or female stress urinary incontinence (SUI) generally occurs when the patient is physically stressed.


In its severest forms, vaginal vault prolapse can result in the distension of the vaginal apex outside of the vagina. An enterocele is a vaginal hernia in which the peritoneal sac containing a portion of the small bowel extends into the rectovaginal space. Vaginal vault prolapse and enterocele represent challenging forms of pelvic disorders for surgeons. These procedures often involve lengthy surgical procedure times.


Urinary incontinence can be characterized by the loss or diminution in the ability to maintain the urethral sphincter closed as the bladder fills with urine. Male or female stress urinary incontinence (SUI) occurs when the patient is physically stressed.


U.S. Pat. Nos. 6,354,991 and 6,896,651 to Gross et al., which are incorporated herein by reference, describe a device and method for treatment of urinary stress incontinence. At least one electrode is implanted in a pelvic muscle of a patient. A control unit receives signals indicative of abdominal stress in the patient and responsive thereto applies an electrical waveform to the electrode which stimulates the muscle to contract, so as to inhibit involuntary urine flow through the patient's urethra due to the stress. U.S. Pat. No. 6,652,449 to Gross et al., which is incorporated herein by reference, describes a device for treatment of a patient's urinary incontinence, including a sensor, which generates a signal responsive to a physiological characteristic indicative of a likelihood of incontinence. A control unit receives the signal from the sensor. At least one electrode is preferably implanted in the patient. The electrode is coupled to cause contraction of the pelvic muscle of the patient responsive to application of electrical energy to the electrode. Responsive to the signal, the control unit applies an electrical waveform to the electrode, so as to inhibit the incontinence.


U.S. Patent Publication No. 2007/0260288 and PCT Patent Publication Nos. WO 2007/106303 and WO 2007/145913, which are hereby incorporated herein by reference, disclose various active implantable stimulation devices having one or more electrodes and a control unit adapted to drive the one or more electrodes to apply current to pelvic tissue, such as the rectum and urethra.


There is a desire to obtain improved fixation of implants, anchors, or stimulation leads within the body of the patient.


SUMMARY OF THE INVENTION

The present invention describes pelvic mesh implants, stimulation leads or systems, and methods for treating pelvic conditions such as incontinence (various forms such as fecal incontinence, stress urinary incontinence, urge incontinence, mixed incontinence, etc.), vaginal prolapse (including various forms such as enterocele, cystocele, rectocele, apical or vault prolapse, uterine descent, etc.), and other conditions caused by muscle and ligament weakness.


Certain embodiments can include a mesh implant adapted for pelvic floor stimulation. In one embodiment, a support structure, e.g., mesh sling or implant, one or more stimulation elements, and an energizing element are included. Leads or electrodes can be positioned in desired stimulation zones of the implant. As such, the implant can include multiple electrically isolated mesh electrode pads.





BRIEF DESCRIPTION OF THE DRAWINGS

The above summary and its identified advantages will become apparent to those skilled in the art to which the invention pertains upon further consideration of the example embodiments depicted and described in the following, to which:



FIG. 1 depicts a multi-zone mesh implant for stimulation and fixation in accordance with embodiments of the present invention;



FIG. 2 depicts a multi-zone mesh implant for stimulation and fixation having a generally contoured configuration;



FIG. 3 depicts a multi-zone mesh implant for stimulation and fixation in a contoured configuration proximate a patient's bladder;



FIG. 4 depicts an example embodiment of an anchor disposed on a portion of an implant to prevent movement of the implant in the body;



FIG. 5 depicts the anchor of FIG. 4 encased in a dissolvable casing;



FIG. 6 depicts the anchor of FIG. 5 in an expanded position after the casing has dissolved;



FIG. 7 depicts another example embodiment of an anchor in a retracted position; and



FIG. 8 depicts the anchor of FIG. 7 in an expanded position.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Referring generally to FIGS. 1-3, example embodiments are shown of an incontinence control implant system 10 capable of being generally contoured or conformed to pelvic organs or tissue within a patient's pelvic cavity. One of the many features of the invention is its ability to provide mechanical support while stimulating nerve and muscle tissue. Implant 10 is designed to generally have a shape and surface area that allows it to come into contact with the nerves and/or muscles of incontinence control structures such as the bladder, urethra, pelvic muscle, bowel and/or rectal tissue.


In one embodiment, implant system 10 has a support structure 12, e.g., mesh (woven or non-woven) sling or implant that supports the organ or tissue, one or more stimulation elements 14 (e.g., leads) that stimulates the nerves or muscle, and an energizing element 15 that transmits a stimulus to the stimulation elements 14. Leads or electrodes 14 can be positioned in desired stimulation zones of implant 10. As such, implant 10 can include multiple isolated conductive electrode pads, patches, regions or zones identified in the figures by the letter A.


Referring particularly to the example embodiment depicted in FIG. 1, zones A are defined within support structure 12 of implant system 10 by one or more frame portions 16 that supports and separates one or more mesh portions 18. Frame portions 16 can separate mesh portions 18 into any of a number of stimulation zones A. In FIG. 1, for example, four stimulation zones A are illustrated. One skilled in the art, however, would understand that implant 10 can be fabricated with any number of stimulation zones.


Turning now to frame portions 16, example embodiments are contemplated having frame portions 16 extending about a perimeter of support structure 12. Intersecting support portions 17 can extend away from the perimeter and either connect with another portion of the perimeter or intersect another intersecting support portion 17. One or more intersecting support portions 17 can extend away from the perimeter. Frame portions 16 and intersecting support portions 17 can be fabricated from any biologically compatible material such as, for example, polypropylene or silicone. Frame 16 portions and intersecting support portions 17 can also be porous or non-porous and rigid, semi-rigid or flexible.


In one embodiment, as illustrated in FIGS. 2 and 3, support structure 12 can be flexed, bent or conformed to the shape of an organ or tissue to be supported and/or stimulated. In an example embodiment, frame portions 16 and the intersecting support portions 17 can be flexed, bent, contoured or molded into a particular shape by a physician so that implant 10 can be placed in contact with the contour of an organ or tissue. Frame portions 16 and intersecting support portions 17 can be fabricated from any material that can retain a particular shape, for example, nitinol and similar wires. In some example embodiments, the material used to retain a particular shape can be coated or covered by frame portions 16 or intersecting support portions 17. Silicone or other like materials can also be provided around the edges or between predetermined stimulation zones A of implant 10 to provide zone separation and to protect from erosion potential.


As illustrated in FIGS. 1-3, mesh portions 18 can be disposed between frame portions 16 and intersecting support portions 17. Mesh portions 18 are generally porous to allow tissue ingrowth and to prevent movement of implant 10 once placed into the patient. Mesh portions 18 can be woven or generally non-woven. Support structure 12, as a whole or in portions, can be fabricated from a molding process, laser cutting or weaving. In another embodiment, mesh portions 18 can also be fabricated from a material similar to frame portions 16 and intersecting support portions 17 that allows it to retain a particular shape.


The shape of implant 10 or pad can vary greatly in geometry and size to better control target stimulation zones for specific anatomical areas of tissue. The shape can also be predetermined during the fabrication process to eliminate or reduce the need of the physician to mold or conform implant 10 to the patient's anatomy. While four zones are generally depicted in the figures, any numbers of zones, zone shapes, and zone configurations can be implemented with the present invention.


Stimulation leads 14 can be selectively placed anywhere along the mesh portions 18 or stimulation zones A during the fabrication process. In one embodiment, mesh portions 18 are made from a conductive material that transfers or carries the signal from stimulation lead 14 through the stimulation zone A. The flexibility of implant 10 allows it to wrap around or generally abut or surround the potential target tissue or zone A to be stimulated. This provides a distinct advantage over previous methods that attempted to merely place an elongate lead adjacent a nerve. Implant 10 allows a greater area of the organ or tissue to be stimulated, thereby eliminating the need for pinpoint precision. Implant 10 is also capable of having tissue ingrowth into mesh portions 18, thereby eliminating the concern of lead migration in the patient.


Mesh portions 18 of implant 10 can also have a particular geometry that permits it to expand, contract, stretch, shrink and the like. The particular geometry may permit implant 10 to better conform to the organ or tissue to be stimulated. The space or size of the pores may be uniform or non-uniform across mesh portions 18. The particular geometry may also assist in the mechanical support of the organ or tissue.


Implant 10 can also have an insulative back layer 20 that insulates and protects the tissue opposite the organ or tissue to be stimulated. Any non-conductive and biocompatible material may be used during the fabrication process. For instance, silicone, rubber or another layer of polypropylene can be used. Insulative layer 20 can be connected to the non-stimulating side of implant 10 by adhesives, molding, welding and the like known to those skilled in the art.


Implant 10 of the present invention also has a control module 26 in operative communication with support structure 12 to control the transmission of the electric current to and through support structure 12. Control module 26 can be implanted into the patient and controlled by a remote control 27. Remote control 27 makes implant 10 electrically active, with stimulation zones A controlled to maximize effectiveness of the stimulation. Zones A within the mesh may be turned on or off independently of one another to adjust stimulation characteristics at the target tissue or zone. The amplitude of the stimulation may also be varied among the zones A to permit the user or a physician to maximize the control of incontinence.


Alternate embodiments of implant 10 also combine the fixation characteristics of mesh with the ability of precision control of the desired area of stimulation. As such, the electrically active mesh can provide both fixation (tissue in-growth) and electrical stimulation (electrode treatment) benefits. As shown in FIGS. 4-8, embodiments of lead 14 can include a sleeve 30. Sleeve 30 can further include one or more fixation devices 32 attached thereto or therealong. Fixation devices 32, in one embodiment, are generally helical or barb in shape or they can include a plurality of extending and/or angled tines 34. Fixation devices 32 can be provided or otherwise incorporated with sleeve 30 or lead 14 anywhere along the length of the sleeve or lead. Such a helical fixation device 32 can provide resistance to back turning and undesirable movement of lead 14 during insertion, placement and deployment of the system. As illustrated in FIG. 4, fixation device 32 can be in multiple locations on a particular lead 14.


In some embodiments, a soluble capsule or casing 36 is provided that surrounds, encases or envelops at least a portion of one or more expandable fixation devices or anchors 32. Expandable fixation anchors 32 can be configured with various known barbs or tines 34, or like elements to promote tissue fixation.


During initial insertion within the body of the patient, capsule 36 encases expandable fixation devices 32 such that tines 34 lay in a generally flat orientation. When capsule 36 dissolves (e.g., automatically, upon application of dissolving agent or substance, or by way of an environmental condition naturally occurring in a patient's body), tines 34 extending therefrom, are released from their flat restrictive state such that tines 34 can engage tissue for fixation. Various levels of dissolvability can be provided with capsule 36 to provide desired or predetermined release of expandable fixation devices 32. The expandable fixation devices 32, or portions thereof, can be constructed of various compatible flexible materials, such as known polymers or metals.


In certain embodiments, as shown in FIGS. 4, 5 and 7, a temperature sensitive adhesive or other known substance can be used to restrict tines 34 in a deployable flat position until a desired or predetermined condition or variable dissolves or otherwise releases the substance to thereby release the tines 34 for fixation. In the example embodiment of FIG. 7, multiple tines 34 can be deployed that extend in opposite directions relative to each other to ensure that lead 14 does not move in any direction.


The embodiment of FIG. 4 illustrates a lead 14 having a sleeve 30 with a helical tip 38. Tip 38 can be adapted (based on shape and material construct) to be in a generally compressed state while lead 14 is placed in a patient. Once placed, tip 38 can spring or expand back to its extended position to resist pull back of sleeve 30 and/or lead 14. Other like design configuration to promote insertion while still facilitating fixation or limiting undesired movement after insertion are envisioned for the sleeve and/or lead as well.


In various embodiments, sleeve 30 and fixation devices 32 of the present invention can be employed with mesh implant or slings to provide advantageous anchoring with target tissue of the patient.


The systems, their various components, structures, features, materials and methods of the present invention may have a number of suitable configurations as shown and described in the previously-incorporated references. Various methods and tools for introducing, deploying, anchoring and manipulating implants or stimulation leads to treat incontinence and prolapse as disclosed in the previously-incorporated references are envisioned for use. The various implant systems 10, features and methods detailed herein are envisioned for use with many known implant, stimulation and repair systems (e.g., for male and female), features and methods, including those disclosed in U.S. Pat. Nos. 7,500,945, 7,407,480, 7,351,197, 7,347,812, 7,303,525, 7,267,645, 7,025,063, 6,911,003, 6,691,711, 6,648,921, and 6,612,977, International Patent Publication Nos. WO 2008/057261 and WO 2007/097994, and U.S. Patent Publication Nos. 2002/151762, 2002/0161382, 2007/0260288, and 2002/147382. Accordingly, the above-identified disclosures are fully incorporated herein by reference in their entirety, with each of the identified publications being incorporated herein by reference in their entirety. As detailed above, the deployable fixation features or anchors can be utilized to selectively anchor leads, implants, or other treatment devices or elements adapted for treating incontinence, prolapse and like conditions.


All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety as if individually incorporated, and include those references incorporated within the identified patents, patent applications and publications.


Obviously, numerous modifications and variations of the present invention are possible in light of the teachings herein. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced other than as specifically described herein.

Claims
  • 1. An implant stimulation system for stimulating tissue of a pelvic region, said system comprising: a formable support structure having a plurality of stimulation zones capable of independently stimulating different areas of a pelvic region, the support structure comprising frame portions separating the stimulation zones that is formable to the tissue being stimulated, the stimulation zones comprising mesh portions connected to the frame portions;at least one lead being in operative communication with each stimulation zone; anda control module in operative communication with the at least one lead to control the stimulus to each of the stimulation zones.
  • 2. The stimulation system of claim 1, further comprising a remote control in operative communication with the control module to allow a user or physician to control the stimulus to the stimulation zones.
  • 3. The stimulation system of claim 1, wherein the mesh portion comprises a conductive material to spread the stimulus over the area of the stimulation zone.
  • 4. The stimulation system of claim 1, wherein the mesh portion comprises pores having a uniform opening across the stimulation zones.
  • 5. The stimulation system of claim 1, wherein the mesh portion comprises pores having a non uniform opening across the stimulation zones.
  • 6. The stimulation system of claim 1, wherein the stimulation zones are simultaneously stimulated.
  • 7. The stimulation system of claim 1, wherein the stimulation zones are selectively stimulated by a user or physician.
  • 8. The stimulation system of claim 1, further comprising at least one fixation device being coupled to at least one of the leads to prevent movement of the lead in a patient.
  • 9. The stimulation system of claim 8, wherein the fixation device comprises one or more tines extending angularly away from the lead.
  • 10. The stimulation system of claim 8, further comprising a capsule encasing at least one fixation device in a collapsed state.
  • 11. The stimulation system of claim 10, wherein the capsule is dissolvable to permit the fixation device to move from a collapsed state to an expanded state.
  • 12. An implant stimulation system for stimulating tissue of a pelvic region, said system comprising: at least one lead being in operative communication with an organ or tissue of a pelvic region;a helical anchor disposed on a tip of the lead;a dissolvable capsule encasing the helical anchor and retaining the helical anchor in a compressed state and allowing the helical anchor to expand to an expanded state upon dissolving; anda control module in operative communication with the at least one lead to control the stimulus thereto.
US Referenced Citations (383)
Number Name Date Kind
2816997 Conrad Dec 1957 A
3628538 Vincent et al. Dec 1971 A
3640284 De Langis Feb 1972 A
3646940 Timm et al. Mar 1972 A
3650276 Burghele et al. Mar 1972 A
3662758 Glover May 1972 A
3667477 Susset et al. Jun 1972 A
3831588 Rindner Aug 1974 A
3866613 Kenny et al. Feb 1975 A
3870051 Brindley Mar 1975 A
3926178 Feldzamen Dec 1975 A
3941136 Bucalo Mar 1976 A
3983865 Shepard Oct 1976 A
3983881 Wickham Oct 1976 A
3999555 Person Dec 1976 A
4010758 Rockland et al. Mar 1977 A
4023562 Hynecek et al. May 1977 A
4023574 Nemec May 1977 A
4030509 Heilman et al. Jun 1977 A
4044774 Corbin et al. Aug 1977 A
4106511 Erlandsson Aug 1978 A
4136684 Scattergood et al. Jan 1979 A
4139006 Corey Feb 1979 A
4153059 Fravel et al. May 1979 A
4157087 Miller et al. Jun 1979 A
4165750 Aleev et al. Aug 1979 A
4177819 Kofsky et al. Dec 1979 A
4222377 Burton Sep 1980 A
4222385 Backhouse Sep 1980 A
4290420 Manetta Sep 1981 A
4387719 Plevnik Jun 1983 A
4402328 Doring Sep 1983 A
4406288 Horwinski et al. Sep 1983 A
4407296 Anderson Oct 1983 A
4414986 Dickhudt et al. Nov 1983 A
4431001 Hakansson et al. Feb 1984 A
4432372 Monroe Feb 1984 A
4457299 Cornwell Jul 1984 A
4492233 Petrofsky et al. Jan 1985 A
4515167 Hochman May 1985 A
4542753 Brenman et al. Sep 1985 A
4550737 Osypka Nov 1985 A
4556061 Barreras et al. Dec 1985 A
4568339 Steer Feb 1986 A
4569351 Tang Feb 1986 A
4571749 Fischell Feb 1986 A
4580578 Barsom Apr 1986 A
4585005 Lue et al. Apr 1986 A
4590949 Pohndorf May 1986 A
4602624 Naples et al. Jul 1986 A
4607639 Tanagho et al. Aug 1986 A
4628942 Sweeney et al. Dec 1986 A
4688575 DuVall Aug 1987 A
4703755 Tanagho et al. Nov 1987 A
4730389 Baudino Mar 1988 A
4731083 Fischell Mar 1988 A
4735205 Chachques et al. Apr 1988 A
4739764 Lue et al. Apr 1988 A
4750494 King Jun 1988 A
4771779 Tanagho et al. Sep 1988 A
4785828 Maurer Nov 1988 A
4825876 Beard May 1989 A
4846191 Brockway et al. Jul 1989 A
4873986 Wallace Oct 1989 A
4878889 Polyak Nov 1989 A
4881526 Johnson et al. Nov 1989 A
4913164 Greene et al. Apr 1990 A
4941874 Sandow et al. Jul 1990 A
5013292 Lemay May 1991 A
5019032 Robertson May 1991 A
5037488 Wienand Aug 1991 A
5082006 Jonasson Jan 1992 A
5094242 Gleason et al. Mar 1992 A
5103835 Yamada et al. Apr 1992 A
5112344 Petros May 1992 A
5113868 Wise et al. May 1992 A
5144948 Andersson et al. Sep 1992 A
5184619 Austin Feb 1993 A
5186170 Varrichio et al. Feb 1993 A
5193539 Schulman et al. Mar 1993 A
5193540 Schulman et al. Mar 1993 A
5199430 Fang et al. Apr 1993 A
5201865 Kuehn Apr 1993 A
5207103 Wise et al. May 1993 A
5211175 Gleason et al. May 1993 A
5233982 Kohl Aug 1993 A
5235980 Varrichio et al. Aug 1993 A
5285781 Brodard Feb 1994 A
5291902 Carman Mar 1994 A
5300093 Koestner et al. Apr 1994 A
5312439 Loeb May 1994 A
5314458 Najafi et al. May 1994 A
5324316 Schulman et al. Jun 1994 A
5324323 Bui Jun 1994 A
5324324 Vachon et al. Jun 1994 A
5324326 Lubin Jun 1994 A
5330505 Cohen Jul 1994 A
5330507 Schwartz Jul 1994 A
5344439 Otten Sep 1994 A
5358514 Schulman et al. Oct 1994 A
5366493 Scheiner et al. Nov 1994 A
5370670 Chancellor Dec 1994 A
5385577 Maurer et al. Jan 1995 A
5391191 Holmstrom Feb 1995 A
5405367 Schulman et al. Apr 1995 A
5411538 Lin May 1995 A
5411548 Carman et al. May 1995 A
5417226 Juma May 1995 A
5423329 Ergas Jun 1995 A
5425751 Baeten et al. Jun 1995 A
5431686 Kroll et al. Jul 1995 A
5452719 Eisman et al. Sep 1995 A
5484445 Knuth Jan 1996 A
5486201 Canfield Jan 1996 A
5508476 Dickenson Apr 1996 A
5518504 Polyak May 1996 A
5520606 Schoolman et al. May 1996 A
5522266 Nicholson et al. Jun 1996 A
5562717 Tippey et al. Oct 1996 A
5564434 Halperin et al. Oct 1996 A
5566680 Urion et al. Oct 1996 A
5568815 Raynes et al. Oct 1996 A
5569351 Menta et al. Oct 1996 A
5571148 Loeb et al. Nov 1996 A
5611515 Benderev et al. Mar 1997 A
5611768 Tutrone, Jr. Mar 1997 A
5611769 Monroe Mar 1997 A
5634462 Tyler et al. Jun 1997 A
5658321 Fayram et al. Aug 1997 A
5693000 Crosby et al. Dec 1997 A
5702428 Tippey et al. Dec 1997 A
5722997 Nedungadi et al. Mar 1998 A
5726624 Caffee et al. Mar 1998 A
5752978 Chancellor May 1998 A
5766229 Bornzin Jun 1998 A
5769873 Zadeh Jun 1998 A
5785666 Costello et al. Jul 1998 A
5803897 Mooreville et al. Sep 1998 A
5807265 Itoigawa et al. Sep 1998 A
5807397 Barreras Sep 1998 A
5824027 Hoffer et al. Oct 1998 A
5833595 Lin Nov 1998 A
5836886 Itoigawa et al. Nov 1998 A
5836994 Bourgeois Nov 1998 A
5842478 Benderev et al. Dec 1998 A
5851226 Skubitz et al. Dec 1998 A
5860425 Benderev et al. Jan 1999 A
5876353 Riff Mar 1999 A
5899909 Claren et al. May 1999 A
5902331 Bonner et al. May 1999 A
5927282 Lenker et al. Jul 1999 A
5931864 Chastain et al. Aug 1999 A
5941903 Zhu et al. Aug 1999 A
5954761 Machek et al. Sep 1999 A
5957920 Baker Sep 1999 A
5957965 Moumane et al. Sep 1999 A
5963097 Garachtchenko et al. Oct 1999 A
5969591 Fung Oct 1999 A
5978712 Suda et al. Nov 1999 A
5984711 Woodward Nov 1999 A
5984854 Ishikawa et al. Nov 1999 A
6002964 Feler et al. Dec 1999 A
6006135 Kast et al. Dec 1999 A
6019729 Itoigawa et al. Feb 2000 A
6026326 Bardy Feb 2000 A
6027456 Feler et al. Feb 2000 A
6038463 Laske et al. Mar 2000 A
6039686 Kovac Mar 2000 A
6042534 Gellman et al. Mar 2000 A
6051017 Loeb et al. Apr 2000 A
6055456 Gerber Apr 2000 A
6061596 Richmond et al. May 2000 A
6078840 Stokes Jun 2000 A
6104955 Bourgeois Aug 2000 A
6104960 Duysens et al. Aug 2000 A
6110101 Tihon et al. Aug 2000 A
6128531 Campbell-Smith Oct 2000 A
6128536 Noack et al. Oct 2000 A
6129658 Delfino et al. Oct 2000 A
6131575 Lenker et al. Oct 2000 A
6135945 Sultan Oct 2000 A
6141594 Flynn et al. Oct 2000 A
6161029 Spreigl et al. Dec 2000 A
6178356 Chastain et al. Jan 2001 B1
6185452 Schulman et al. Feb 2001 B1
6208894 Schulman et al. Mar 2001 B1
6221024 Miesel Apr 2001 B1
6238423 Bardy May 2001 B1
6240315 Mo et al. May 2001 B1
6240316 Richmond et al. May 2001 B1
6243607 Mintchev et al. Jun 2001 B1
6248083 Smith et al. Jun 2001 B1
6253108 Rosborough et al. Jun 2001 B1
6259949 Rosborough et al. Jul 2001 B1
6263241 Rosborough et al. Jul 2001 B1
6266557 Roe et al. Jul 2001 B1
6266564 Hill et al. Jul 2001 B1
6304786 Heil et al. Oct 2001 B1
6328686 Kovac Dec 2001 B1
6328687 Karram et al. Dec 2001 B1
6341236 Osorio et al. Jan 2002 B1
6354991 Gross et al. Mar 2002 B1
6356788 Boveja et al. Mar 2002 B2
6360750 Gerber et al. Mar 2002 B1
6366814 Boveja et al. Apr 2002 B1
6382214 Raz et al. May 2002 B1
6393323 Sawan May 2002 B1
6397109 Cammilli et al. May 2002 B1
6407308 Roe et al. Jun 2002 B1
6418930 Fowler Jul 2002 B1
6477414 Silvian Nov 2002 B1
6478727 Scetbon Nov 2002 B2
6505074 Boveja Jan 2003 B2
6505082 Scheiner et al. Jan 2003 B1
6572543 Christopherson et al. Jun 2003 B1
6582441 He et al. Jun 2003 B1
6585660 Dorando et al. Jul 2003 B2
6600956 Maschino et al. Jul 2003 B2
6612977 Staskin et al. Sep 2003 B2
6641524 Kovac Nov 2003 B2
6641525 Rocheleau et al. Nov 2003 B2
6648921 Anderson et al. Nov 2003 B2
6650943 Whitehurst et al. Nov 2003 B1
6652449 Gross et al. Nov 2003 B1
6652450 Neisz et al. Nov 2003 B2
6652499 Edgren et al. Nov 2003 B1
6658297 Loeb Dec 2003 B2
6659936 Furness et al. Dec 2003 B1
6691711 Raz et al. Feb 2004 B2
6712772 Cohen et al. Mar 2004 B2
6735474 Loeb et al. May 2004 B1
6738674 Osypka May 2004 B2
6745079 King Jun 2004 B2
6764472 Burke et al. Jul 2004 B1
6802807 Anderson et al. Oct 2004 B2
6836684 Rijkhoff et al. Dec 2004 B1
6862480 Cohen et al. Mar 2005 B2
6885894 Stessman Apr 2005 B2
6896651 Gross et al. May 2005 B2
6911003 Anderson et al. Jun 2005 B2
6915162 Noren et al. Jul 2005 B2
6941171 Mann et al. Sep 2005 B2
6952613 Swoyer et al. Oct 2005 B2
6964643 Hovland et al. Nov 2005 B2
6964699 Carns et al. Nov 2005 B1
6971393 Mamo et al. Dec 2005 B1
7011622 Kuyava et al. Mar 2006 B2
7025063 Snitkin et al. Apr 2006 B2
7054689 Whitehurst et al. May 2006 B1
7070556 Anderson et al. Jul 2006 B2
7079882 Schmidt Jul 2006 B1
7120499 Thrope et al. Oct 2006 B2
7203548 Whitehurst et al. Apr 2007 B2
7217237 Wassemann et al. May 2007 B2
7267645 Anderson et al. Sep 2007 B2
7292890 Whitehurst et al. Nov 2007 B2
7303525 Watschke et al. Dec 2007 B2
7319905 Morgan et al. Jan 2008 B1
7328068 Spinelli et al. Feb 2008 B2
7330764 Swoyer et al. Feb 2008 B2
7343202 Mrva et al. Mar 2008 B2
7347812 Mellier Mar 2008 B2
7351197 Montpetit et al. Apr 2008 B2
7359751 Erickson et al. Apr 2008 B1
7376467 Thrope et al. May 2008 B2
7376468 King et al. May 2008 B2
7384390 Furness et al. Jun 2008 B2
7387603 Gross et al. Jun 2008 B2
7407480 Anderson et al. Aug 2008 B2
7412289 Malonek et al. Aug 2008 B2
7437193 Parramon et al. Oct 2008 B2
7450987 Varrichio et al. Nov 2008 B2
7500945 Cox et al. Mar 2009 B2
7565198 Bennett et al. Jul 2009 B2
7582053 Gross et al. Sep 2009 B2
7582070 Goode et al. Sep 2009 B2
7613516 Cohen et al. Nov 2009 B2
7628795 Karwoski et al. Dec 2009 B2
7647113 Wirbisky et al. Jan 2010 B2
7658743 Ulmsten Feb 2010 B2
7686760 Anderson et al. Mar 2010 B2
7715920 Rondoni et al. May 2010 B2
7725197 Soltis et al. May 2010 B2
7742817 Malinowski et al. Jun 2010 B2
7769472 Gerber Aug 2010 B2
7771345 O'Donnell Aug 2010 B1
7778703 Gross et al. Aug 2010 B2
7860570 Whitehurst et al. Dec 2010 B2
7890176 Jaax et al. Feb 2011 B2
7930039 Olson Apr 2011 B2
8019443 Schleicher et al. Sep 2011 B2
8052731 Soltis et al. Nov 2011 B2
8083663 Gross et al. Dec 2011 B2
20010002441 Boveja May 2001 A1
20010003799 Boveja Jun 2001 A1
20010018549 Scetbon Aug 2001 A1
20020055761 Mann et al. May 2002 A1
20020099259 Anderson et al. Jul 2002 A1
20020147382 Neisz et al. Oct 2002 A1
20020161382 Neisz et al. Oct 2002 A1
20020165566 Ulmsten Nov 2002 A1
20030018365 Loeb Jan 2003 A1
20030023296 Osypka Jan 2003 A1
20030028232 Camps et al. Feb 2003 A1
20030060868 Janke et al. Mar 2003 A1
20030144575 Forsell Jul 2003 A1
20030171644 Anderson et al. Sep 2003 A1
20030199961 Bjorklund et al. Oct 2003 A1
20030236557 Whitehurst et al. Dec 2003 A1
20030236558 Whitehurst et al. Dec 2003 A1
20040015057 Rocheleau et al. Jan 2004 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040015205 Whitehurst et al. Jan 2004 A1
20040039453 Anderson et al. Feb 2004 A1
20040059392 Parramon et al. Mar 2004 A1
20040068203 Gellman et al. Apr 2004 A1
20040093053 Gerber et al. May 2004 A1
20040152999 Cohen et al. Aug 2004 A1
20040242956 Scorvo Dec 2004 A1
20040248979 Brettman et al. Dec 2004 A1
20050038489 Grill Feb 2005 A1
20050043580 Watschke et al. Feb 2005 A1
20050049648 Cohen et al. Mar 2005 A1
20050055063 Loeb et al. Mar 2005 A1
20050065395 Mellier Mar 2005 A1
20050113877 Spinelli et al. May 2005 A1
20050113881 Gross et al. May 2005 A1
20050119710 Furness et al. Jun 2005 A1
20050143618 Anderson et al. Jun 2005 A1
20050149156 Libbus et al. Jul 2005 A1
20050216069 Cohen et al. Sep 2005 A1
20050228346 Goode et al. Oct 2005 A1
20050245787 Cox et al. Nov 2005 A1
20050245874 Carrez et al. Nov 2005 A1
20050250977 Montpetit et al. Nov 2005 A1
20050256367 Banik Nov 2005 A1
20050277994 McNamee et al. Dec 2005 A1
20050283235 Kugler et al. Dec 2005 A1
20060004421 Bennett et al. Jan 2006 A1
20060004429 Mrva et al. Jan 2006 A1
20060135845 Kuyava et al. Jun 2006 A1
20060149345 Boggs, II et al. Jul 2006 A1
20060241733 Zhang et al. Oct 2006 A1
20060265027 Vaingast et al. Nov 2006 A1
20060287571 Gozzi et al. Dec 2006 A1
20070021650 Rocheleau et al. Jan 2007 A1
20070027514 Gerber Feb 2007 A1
20070043416 Callas et al. Feb 2007 A1
20070100411 Bonde May 2007 A1
20070123952 Strother et al. May 2007 A1
20070179559 Giftakis et al. Aug 2007 A1
20070185541 DiUbaldi et al. Aug 2007 A1
20070239224 Bennett et al. Oct 2007 A1
20070253997 Giftakis et al. Nov 2007 A1
20070253998 Giftakis et al. Nov 2007 A1
20070255333 Giftakis et al. Nov 2007 A1
20070255341 Giftakis et al. Nov 2007 A1
20070260288 Gross Nov 2007 A1
20070265675 Lund et al. Nov 2007 A1
20080009914 Buysman et al. Jan 2008 A1
20080033493 Deckman et al. Feb 2008 A1
20080071321 Boggs, II et al. Mar 2008 A1
20080109045 Gross et al. May 2008 A1
20080114433 Sage et al. May 2008 A1
20080132969 Bennett et al. Jun 2008 A1
20080242918 Gross et al. Oct 2008 A1
20090012592 Buysman et al. Jan 2009 A1
20090036946 Cohen et al. Feb 2009 A1
20090043356 Longhini et al. Feb 2009 A1
20090096288 Nguyen Apr 2009 A1
20090157091 Buysman Jun 2009 A1
20090254145 Gross et al. Oct 2009 A1
20090259280 Wilkin et al. Oct 2009 A1
20100049289 Lund et al. Feb 2010 A1
20100076254 Jimenez et al. Mar 2010 A1
20100076255 Robertson et al. Mar 2010 A1
20100114510 Vaingast et al. May 2010 A1
20100160716 Snow Jun 2010 A1
20100217340 Watschke et al. Aug 2010 A1
20110015738 Vaingast et al. Jan 2011 A1
20110270269 Swoyer et al. Nov 2011 A1
20110301662 Bar-Yoseph et al. Dec 2011 A1
20120095478 Wang et al. Apr 2012 A1
Foreign Referenced Citations (59)
Number Date Country
8506522.6 Jun 1985 DE
0245547 Nov 1987 EP
1119314 Aug 2001 EP
1661600 May 2006 EP
2309388 Jul 1997 GB
52146088 Dec 1977 JP
2002521153 Jul 2002 JP
2003506145 Feb 2003 JP
2004515277 May 2004 JP
WO9012617 Jan 1990 WO
9012617 Nov 1990 WO
9604955 Feb 1996 WO
WO9604955 Feb 1996 WO
9632916 Oct 1996 WO
WO9632916 Oct 1996 WO
9817190 Apr 1998 WO
WO9817190 Apr 1998 WO
0000082 Jan 2000 WO
0001320 Jan 2000 WO
WO0000082 Jan 2000 WO
WO0001320 Jan 2000 WO
0006246 Feb 2000 WO
0019939 Apr 2000 WO
0019940 Apr 2000 WO
WO0019939 Apr 2000 WO
WO0019940 Apr 2000 WO
0110357 Feb 2001 WO
WO0147440 Jul 2001 WO
WO0269781 Jan 2002 WO
0239890 May 2002 WO
WO0239890 May 2002 WO
0245774 Jun 2002 WO
02069781 Sep 2002 WO
02078592 Oct 2002 WO
WO02078592 Oct 2002 WO
03002192 Jan 2003 WO
WO03002192 Jan 2003 WO
WO03094693 Nov 2003 WO
WO2004047914 Jun 2004 WO
WO2005122954 Dec 2005 WO
WO2006014971 Feb 2006 WO
2006047833 May 2006 WO
WO2006047833 May 2006 WO
WO2006126201 Nov 2006 WO
WO2007025354 Mar 2007 WO
2007097994 Aug 2007 WO
WO2007097994 Aug 2007 WO
WO2007106303 Sep 2007 WO
2007126632 Nov 2007 WO
WO2007126632 Nov 2007 WO
2007145913 Dec 2007 WO
WO2007145913 Dec 2007 WO
WO2008057261 May 2008 WO
WO2008121109 Oct 2008 WO
WO2009026078 Feb 2009 WO
WO2009094431 Jul 2009 WO
2010107751 Sep 2010 WO
WO2010107751 Sep 2010 WO
WO2010107900 Sep 2010 WO
Non-Patent Literature Citations (78)
Entry
O'Donnell, Pat D., Urinary Incontinence, Mosby Year Book, Inc pp. 197-202 (1997).
Chai, et al., “percutaneous Scral Third nerve Root Neurostimulation Improves Symptoms and Normalizes Urinary HB-EGF Levels and Antiproliferative Activity in Patients with Interstitial Cystitis”, Urology, 55(5), pp. 643-646k, May 2000.
Agazzi E., et al. “Percutaneous Tibial Nerve Stimulation and Short Latency Somatosensory Evoked Ptentials: Preliminary Reports” Eur. Urol Suppl. 2007; 6(2): 141.
Arabi, K. et al. “Implantable Multiprogrammable Microstimulator Dedicated to Bladder Control”, Med. & Biol. Eng. & Comput., 1996, 34, 9-12.
Bosch, J.L. “Electrical neuromodulatory therapy in female voiding dysfunction.” BJU Int. Sep. 2006;98 Suppl 1:43-8; discussion 49. Review.
Bosch, J.L.H.R, “The Bion Device: A Minimally Invasive Implantable Ministimulator for Pudendal Nerve Neuromodulation in Patients with Detrusor Overactivity Incontinence”, Urol. Clin. N. Am 32(2005) 109-112.
Bosch, J.L.H.R, et al. “The long term effect of electrostimulation of the pelvic floor on painful bladder syndrome/interstitial cystitis patients”, Neurourology and Urodynamics 2008;27(7 suppl).
Bresler, Larissa et al., “Effective Methods of Pelvic Plexus Nerve and Bladder Stimulation in Anesthetized Animal Mode” J. Rehab. Res.& Dev. 49(4) 2008 627-638.
Brindley, G.S. “Electrolytic Current-Control Elements for Surgically Implanted Electrical Devices”, Med. & Biol. Eng. & Comput., 1986, 24, 439-41.
Caldwell, K.P.S. “The Use of Electrial Stimulation in Urinary Retention and Incontinence [Abridged].” Section of Urology, vol. 61, pp. 35-39, Jul. 1968.
Caldwell, K.P.S. et al. “Stress Incontinenece in Females: Report on 31 Cases Treated By Electrical Implant.” J. Obstet. Gynaec. Brit. Cwlth vol. 75, pp. 777-780, Jul. 1968.
Caraballo, et al., “Sacral Nerve Stimulation as a Treatment for urge incontinence and Associated Pelvic Floor Disorders at a Pelvic Floor Center: A Follow-Up Study”, Urology, 57(6 Suppl 1), p. 121, Jun. 2001.
Chai, et al., “Modified Techniques of S3 Foramen Localization and Lead Implantation in S3 Neuromodulation”, Urology 58: 786-790, 2001.
Dietz et al., Mechanical Properties of Urogynecologic Implant Materials, Int. Urogynecol J. (2003) 14:239-243.
Diokno, Ananias et al., “A Simplified Method of Implanting a Neuromodulator Device” J. Urol. 169, 1466-69 2003.
Donaldson, N “Design of an Implant for Preventing Incontinence After Spinal Cord Injury”, Artif Organs, vol. 32, No. 8, 2008.
Fall, et al., “Electrical Stimulation in Interstitial Cystiitis”, Journal of urology 123(2), pp. 192-195, Feb. 1980.
Fall, et al., “Electrical Stimulation; A Physiologic Approach to the Treatment of Urinary Incontinence”, Urologic of North America vol. 18 N. 2, May 1991 pp. 393-407.
Gaunt, RA et al., “Control of urinary bladder function with devices: successes and failures.”, Prog Brain Res. 2006;152:163-94.
Green, Roger et al. “Objective Methods for Evaluation of Interferential Therapy in the Treatment of Incontinence” IEE Transactions on Biol. Eng. 37(6) 1990 615-623.
Grill WM, et al, “Emerging clinical applications of electrical stimulation: opportunities for restoration of function,” J Rehabil Res Dev 2001 38(6): 641-53.
Herbison GP, et al “Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults”, The Cochrane Library 2009 Issue 2 1-29 (31 pages).
Ishikawa, N. et al., “Development of a non-invasive treatment system for urinary incontinence using a functional continuous magnetic stimulator (FCMS)” Med. Biol. Eng. Comput., 1998, 36, 704-10.
Kirkham, APS, “Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator” Spinal Cord (2002) 40, 272-81.
Medtronic “Interstim Therapy: Implant Manual” (32 pps) 2006.
Merrill, Daniel C., et al., “Treatment with Electrical Stimulation of the Pelvic Floor”, Rology, Jan. 1975, vol. V, No. 1, pp. 67-72.
Odagaki, M. et al. “Comparison of Current Distribution Based on Tissue Inhomogeneity in Magnetic Stimulation for Treatment of Urinary Incontinence”, IEEE Transactions on Magnetics, vol. 41, No. 10, Oct. 2005.
O'Riordan, J.M., et al. “Sacral nerve stimulation for fecal incontinence” Ir J Med Sci (2008) 177:117-119.
Petrofsky, J. “A Transurethral Electrical Stimulator”, J. Clin. Eng. 17(2), 1992, 151-56.
Provost, B. “Proposed new bladder volume monitoring device based on impedance measurement”, Med. Biol. Eng. Comput., 1997, 35, 691-694.
Sherman, ND, et al. “Current and future techniques of neuromodulation for bladder dysfunction”, Curr Urol Rep. Nov. 2007;8(6):448-54.
Soumendra, D, et al “Sacral neurostimulation for urinary retention: 10-year experience from on UK centre” BJU International 101,192-96 (2007).
Starkman, J. et al. “Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation”, Int Urogynecol J (2008) 19:277-282.
Sutherland, S, et al. “Sacral Nerve Stimulation for Voiding Dysfunction: One Institution's 11-Year Experience”, Neurourology and Urodynamics 26:19-28 (2007).
Washington, B. et al. “Implant infection after two-stage sacral nerve stimulator placement”, Int Urogynecol J (2007) 18:1477-1480.
Wenzel, B. et al. “Detecting the Onset of Hyper-Reflective Bladder Contractions from the Electrical Activity of the Pudendal Nerve”, IEE Trans. Neural Sys. Rehab. Eng. 13(3) 2005 428-435.
White, W., et al “Incidence and Predictors of Complications With Sacral Neuromodulation”, Urology 73: 731-735, 2009.
Whiteside JL, “Lead placement and associated nerve distribution of an implantable periurethral electrostimulator.” Int Urogynecol J Pelvic Floor Dysfunct. Mar. 2009;20(3):325-9.
Yamamoto et al., “Optimal parameters for effective electrical stimulation of the anal sphincters in a child with fecal incontinenece: preliminary report,” Pediatr. Surg. Int. (1993) 8:132-137.
Yamanishi et al., “Electrical Stimulation for Stress incontinence”, Int. Urogynecol j (1998) 9:281-290 Springer Verlag London ltd.
Zermann, et al., “Sacral nerve Stimulation for Pain Relief in Interstitial Cystitis” Urol. Int., 65(2), pp. 120-121, 2000.
Zonnervijlle, E., et al., “Dynamic graciloplasty for urinary incontinence: the potential for sequential closed-loop stimulation” Med. Eng. Phy. 25 (2003) 755-63.
Office Action from Japanese Patent Application No. 2008-557294, mailed Jan. 10, 2012.
Notification of a First Office Action from Chinese Patent Application No. 200780007709.2, mailed Sep. 27, 2010.
International Search Report and Written Opinion of PCT/US2007/004474, filed on Feb. 22, 2007.
Extended European Search Report for European Patent Application No. 10176162.5, mailed Apr. 28, 2011.
International Search Report and Written Opinion for PCT/US2011/023677, mailed Apr. 21, 2011.
International Search Report and Written Opinion for PCT/US2007/000112, filed Jan. 3, 2007.
Partial European Search Report from European Patent Application No. 10176162.5, mailed Jan. 21, 2011.
Dietz et al., “Mechanical Properties of Urogynecologic Implant Materials”, Int. Urogynecol J. (2003) 14:239-243.
Iglesia et al., “The Use of Mesh in Gynecologic Surgery”, Int. Urogynecol J. (1997) 8:105-115.
U.S. Appl. No. 60/578,742, filed Jun. 10, 2004.
U.S. Appl. No. 12/406,434, filed Mar. 18, 2009.
U.S. Appl. No. 60/779,219, filed Mar. 3, 2006.
Office Action from Israel Patent Application No. 162193, dated Mar. 1, 2012.
A first Communication issued by the European Patent Office for European Patent Application No. 07795734.8, dated Nov. 17, 2010.
A supplementary European Search Report for European Patent Application No. 02793278.9, dated Feb. 14, 2011.
Yamanishi et al., “Electrical Stimulation for Stress Incontinence,” Int. Urogynecol J (1998) 9:281-290 Springer-Verlag London Ltd.
Yamamoto et al., “Optimal parameters for effective electrical stimulation of the anal sphincters in a child with fecal incontinence: preliminary report,” Pediatr Surg Int (1993) 8:132-137.
U.S. Appl. No. 60/803,954, filed Jun. 5, 2006.
U.S. Appl. No. 60/805,036, filed Jun. 16, 2006.
Notification of a First Office Action from Chinese Patent Application No. 200780021028.1, issued Jun. 1, 2010.
Examiner's First Report from Australian Patent Application No. 2007258756, dated Jul. 22, 2011.
U.S. Appl. No. 60/091,762, filed Jul. 6, 1998.
Merrill Daniel C. et al., “Treatment with Electrical Stimulation of the Pelvic Floor”, Urology, Jan. 1975, vol. V, No. 1, pp. 67-72.
Chai et al., “Percutaneous Sacral Third Nerve Root Neurostimulation Improves Symptoms and Normalizes Urinary HB-EGF Levels and Antiproliferative Activity in Patients with Interstitial Cystitis”, Urology, 55(5), pp. 643-646, May 2000.
Fall et al., “Electrical Stimulation in Interstitial Cystitis”, Journal of Urology, 123(2), pp. 192-195, Feb. 1980.
Zermann et al., “Sacral Nerve Stimulation for Pain Relief in Interstitial Cystitis”, Urol. Int., 65(2), pp. 120-121, 2000.
Caraballo et al., “Sacral Nerve Stimulation as a Treatment for urge Incontinence and Associated Pelvic Floor Disorders at a Pelvic Floor Center: A Follow-Up Study”, Urology, 57(6 Suppl 1), p. 121, Jun. 2001.
P.D. O'Donnel ed., Urinary Incontinence, Chap. 26, 1997, Mosby Publishers, St. Louis, MI pp. 197-202.
Medtronic®'s “InterStim Therapy for Urinary Control-Patient Stories”, 1997, Medtronic Inc., Spring Lake Park, MN, 2 pages. (http://webprod1.medtronic.com/neuro/interstim/4Bsize.html).
Summary of Safety and Effectiveness of Medtronic® Interstim® Sacral Nerve Stimulation (SNS) TM System, Sep. 1997, Medtronic Inc., Spring Lake Park, MN, 2 pages.
Medtronic®'s InterStim Therapy for Urinary..: “for People with Bladder Control Problem”, 1997, Medtronic Inc., Spring Lake Park, MN, 2 pages. (http://webprod1.medtronic.com/neuro/interstim/1types.html).
Caldwell, K.P.S. et al. “Urethral Pressure Recordings in Male Incontinents Under Electrical Stimulation.” Investigative Urology vol. 5, No. 6, pp. 572-579, May 1968.
Caldwell, K.P.S. et al. “Stress Incontinence in Females: Report on 31 Cases Treated by Electrical Implant.” J. Obstet. Gynaec. Brit. Cwlth vol. 75, pp. 777-780, Jul. 1968.
Caldwell, K.P.S. “The Use of Electrical Stimulation in Urinary Retention and Incontinence [Abridged].” Section of Urology, vol. 61, pp. 35-39, Jul. 1968.
Caldwell, K.P.S. “Electrical Stimulation.”, Sphincter Research Unit, Royal Devon and Exeter Hospital, Exeter (England), Urol. Int. 29: 225, 1974. (1 page).
European Search Report and Written Opinion of 06011641.5 completed Aug. 21, 2006.
Related Publications (1)
Number Date Country
20110160793 A1 Jun 2011 US
Provisional Applications (2)
Number Date Country
61291368 Dec 2009 US
61291362 Dec 2009 US